Is heutagogy the future of education?
Fred Garnett, an educationalist, from the Heutagogy Stakeholder Group - a UNESCO initiative. "Humans developed the capability of 'social learning' over millennia before settlements enabled the development of 'civilisation'. We then invented education formalising what we had previously learnt informally....
Source: wordpress.com
Milasen - a drug developed for a single patient.
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease | NEJM: Summary Genome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments. We describe how molecular diagnosis of a rare, fatal neurodegenerative condition led to the...
Source: nejm.org
The Digital Future of Education: Heutagogy and the Digital Future of Education Presentation at DTCE Manchester University
The Digital Future of Education: Heutagogy and the Digital Future of Education Presentation at DTCE Manchester University This is an overview of Fred Garnett's work on digital projects since 1995 and how it might inform us about the future.
Source: wordpress.com
Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study:
Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study: Objective To examine the association of long term intake of gluten with the development of incident coronary heart disease.
Design Prospective cohort study.
Setting and participants...
Source: bmj.com
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial:
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial: This randomized trial reports that in patients with proliferative diabetic retinopathy, ranibizumab treatment resulted in visual acuity that was noninferior to panretinal photocoagulation...
Source: jamanetwork.com
https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fsecure.jbs.elsevierhealth.com%3A443%2Faction%2FgetSharedSiteSession%3Fredirect%3Dhttp%253A%252F%252Fwww.ejog.org%252Fretrieve%252Fpii%252FS0301211515003243%253Fcc%25253Dy%26rc%3D0%26code%3Deuro-site&rc=1
https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fsecure.jbs.elsevierhealth.com%3A443%2Faction%2FgetSharedSiteSession%3Fredirect%3Dhttp%253A%252F%252Fwww.ejog.org%252Fretrieve%252Fpii%252FS0301211515003243%253Fcc%25253Dy%26rc%3D0%26code%3Deuro-site&rc=1
Source: elsevierhealth.com
RSS feed